Latest news
PODD Maintained by Canaccord Genuity -- Price Target Lowered to $179 - GuruFocusGuruFocus · Fri, 07 Aug 2026 05:00:19 GMTUBS Adjusts Insulet Price Target to $150 From $174, Maintains Neutral Rating - MoomooMoomoo · Fri, 07 Aug 2026 04:25:30 GMTRBC Capital Adjusts Price Target on Insulet to $160 From $245, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 03:22:56 GMTPODD Maintained by TD Cowen -- Price Target Lowered to $144 - GuruFocusGuruFocus · Fri, 07 Aug 2026 00:54:12 GMTPODD Maintained by UBS -- Price Target Lowered to $150 - GuruFocusGuruFocus · Thu, 06 Aug 2026 22:02:13 GMTPODD Maintained by Bernstein -- Price Target Lowered to $175 - GuruFocusGuruFocus · Thu, 06 Aug 2026 21:02:44 GMTPODD Maintained by RBC Capital -- Price Target Lowered to $160 - GuruFocusGuruFocus · Thu, 06 Aug 2026 20:43:52 GMTAnalysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 20:34:00 GMT